

**7-5/2013/EU/WC-0226**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organisation**  
**(International Cell)**

FDA Bhawan, Kotla Road  
New Delhi-110002

Dated **07 OCT 2019**

To  
**M/s. Emcure Pharmaceuticals Limited,**  
**D-24, D-24/1, M.I.D.C., Kurkumbh,**  
**Taluka: Daund, District.Pune-413 802.**

**SUB: Written Confirmation of M/s. Emcure Pharmaceuticals Limited, D-24, D-24/1, M.I.D.C., Kurkumbh, Taluka: Daund, District.Pune-413 802 as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.**

Sir,

Please refer to your application submitted to CDSCO, West Zone, Mumbai and the recommendation received from DDC (I), West Zone, Mumbai on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

| Annexure No. | No. of Products | Date of issue | Validity   |
|--------------|-----------------|---------------|------------|
| 01           | 56              | 07 OCT 2019   | 02/07/2022 |
| 02           | 14              | 07 OCT 2019   | 02/07/2022 |

Yours faithfully,



(Dr. V. G. Somani)  
Drugs Controller General (India)

g/c

4-10-19



GOVERNMENT OF INDIA  
MINISTRY OF HEALTH & FAMILY WELFARE  
Central Drugs Standard Control Organization

WC-0226

CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: **M/s. Emcure Pharmaceuticals Limited,  
D-24, D-24/1, M.I.D.C., Kurkumbh,  
Taluka: Daund, District.Pune-413 802.**

2. Manufacturer's license Number: **25-PD/164**

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

**As per list enclosed at Annexure- 01 & 02**

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7):

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

**Date of Inspection of the plant: 24<sup>th</sup> & 25<sup>th</sup> June 2019**

**The Written Confirmation remains valid until: 02<sup>nd</sup> July, 2022**

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

**Address of the issuing regulatory authority: Central Drugs Standard Control Organisation  
FDA Bhawan, Kotla Road,  
New Delhi- 110 002, India.**

**Name and function of responsible person: Dr.V.G.Somani  
Drugs Controller General (India).**

**E-mail:  
Telephone no.:  
Fax no.:**

**dci@nic.in,  
+91-11-23236965  
+91-11-23236973**

Signature

Stamp of the authority and date



**07 OCT 2019**



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

**Name and Address of site: M/s. Emcure Pharmaceuticals Limited,**  
D-24, D-24/1, M.I.D.C., Kurkumbh,  
Taluka: Daund, District.Pune-413 802.

**List of APIs:**

| Sl. No. | Name of the Active Substance (S)      | Activity(ies)           |
|---------|---------------------------------------|-------------------------|
| 1.      | Acetazolamide USP/ Ph. Eur.           | Manufacturing & Packing |
| 2.      | Bendamustine Hydrochloride IH         | Manufacturing & Packing |
| 3.      | Busulfan USP                          | Manufacturing & Packing |
| 4.      | Cyclophosphamide USP                  | Manufacturing & Packing |
| 5.      | Dexketoprofen Trometamol IH           | Manufacturing & Packing |
| 6.      | Esomeprazole Sodium IH                | Manufacturing & Packing |
| 7.      | Eszopiclone IH                        | Manufacturing & Packing |
| 8.      | Gemcitabine Hydrochloride USP         | Manufacturing & Packing |
| 9.      | Irinotecan Hydrochloride USP          | Manufacturing & Packing |
| 10.     | Oxaliplatin USP                       | Manufacturing & Packing |
| 11.     | Palonosetron Hydrochloride IH         | Manufacturing & Packing |
| 12.     | Ritonavir USP                         | Manufacturing & Packing |
| 13.     | Rizatriptan Benzoate USP              | Manufacturing & Packing |
| 14.     | Sevelamer Carbonate IH                | Manufacturing & Packing |
| 15.     | Sevelamer Hydrochloride IH            | Manufacturing & Packing |
| 16.     | Topotecan Hydrochloride Trihydrate IH | Manufacturing & Packing |
| 17.     | Zoledronic Acid IH                    | Manufacturing & Packing |
| 18.     | Zolmitriptan IH                       | Manufacturing & Packing |
| 19.     | Acamprosate Calcium IH                | Manufacturing & Packing |
| 20.     | Atazanavir Sulfate IH                 | Manufacturing & Packing |
| 21.     | Busulfan Ph. Eur.                     | Manufacturing & Packing |
| 22.     | Carmustine USP / Ph. Eur,             | Manufacturing & Packing |
| 23.     | Colesevelam Hydrochloride IH          | Manufacturing & Packing |
| 24.     | Cyclophosphamide Ph. Eur.             | Manufacturing & Packing |
| 25.     | Dapoxetine Hydrochloride IH           | Manufacturing & Packing |
| 26.     | Decitabine Monohydrate IH             | Manufacturing & Packing |
| 27.     | Dexmedetomidine Hydrochloride USP     | Manufacturing & Packing |
| 28.     | Docetaxel Trihydrate USP / Ph. Eur.   | Manufacturing & Packing |
| 29.     | Etodolac USP                          | Manufacturing & Packing |
| 30.     | Ethacrynic Acid USP                   | Manufacturing & Packing |
| 31.     | Febuxostat IH                         | Manufacturing & Packing |
| 32.     | Flecainide Acetate USP / Ph. Eur.     | Manufacturing & Packing |

9/2/19  
for 4-12-19

12



GOVERNMENT OF INDIA  
MINISTRY OF HEALTH & FAMILY WELFARE  
Central Drugs Standard Control Organization

CERTIFICATE NO. :Annexure- 01

WC 0226

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and Address of site: M/s. Emcure Pharmaceuticals Limited,  
D-24, D-24/1, M.I.D.C., Kurkumbh,  
Taluka: Daund, District.Pune-413 802.

List of APIs:

| Sl. No. | Name of the Active Substance (S)        | Activity(ies)           |
|---------|---|-------------------------|
| 33.     | Gemcitabine Hydrochloride Ph. Eur.      | Manufacturing & Packing |
| 34.     | Iron Sucrose Complex IH                 | Manufacturing & Packing |
| 35.     | Iron Sucrose Complex Solution IH        | Manufacturing & Packing |
| 36.     | Ketorolac Tromethamine USP              | Manufacturing & Packing |
| 37.     | Leflunomide USP / Ph.Eur.               | Manufacturing & Packing |
| 38.     | Melphalan Hydrochloride IH              | Manufacturing & Packing |
| 39.     | Memantine Hydrochloride USP             | Manufacturing & Packing |
| 40.     | Metoclopramide Hydrochloride USP        | Manufacturing & Packing |
| 41.     | Mycophenolate Mofetil USP / Ph. Eur.    | Manufacturing & Packing |
| 42.     | Neostigmine Methylsulfate USP           | Manufacturing & Packing |
| 43.     | Oxaliplatin Ph.Eur.                     | Manufacturing & Packing |
| 44.     | Pantoprazole Sodium USP                 | Manufacturing & Packing |
| 45.     | Pemetrexed Disodium Hemipentahydrate IH | Manufacturing & Packing |
| 46.     | Perphenazine USP                        | Manufacturing & Packing |
| 47.     | Promethazine Hydrochloride USP          | Manufacturing & Packing |
| 48.     | Propafenone Hydrochloride USP           | Manufacturing & Packing |
| 49.     | Propofol USP / Ph. Eur.                 | Manufacturing & Packing |
| 50.     | Rizatriptan Benzoate Ph. Eur.           | Manufacturing & Packing |
| 51.     | Ropivacaine Hydrochloride USP           | Manufacturing & Packing |
| 52.     | Rivastigmine Tartrate USP               | Manufacturing & Packing |
| 53.     | Sulfamethoxazole USP                    | Manufacturing & Packing |
| 54.     | Thiotepa USP                            | Manufacturing & Packing |
| 55.     | Tolterodine Tartrate IH                 | Manufacturing & Packing |
| 56.     | Zileuton USP                            | Manufacturing & Packing |

ITEM(S) Fifty Six (56) Only

The Written Confirmation remains valid until: 02<sup>nd</sup> July, 2022

Signature

*[Handwritten Signature]*  
4-10-14

Stamp of the authority and date



07 OCT 2019



GOVERNMENT OF INDIA  
MINISTRY OF HEALTH & FAMILY WELFARE  
Central Drugs Standard Control Organization

CERTIFICATE NO. : **Annexure - 02**  
**WC-0226**

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: **M/s. Emcure Pharmaceuticals Limited,**  
**D-24, D-24/1, M.I.D.C., Kurkumbh,**  
**Taluka: Daund, District.Pune-413 802.**

List of APIs:

| S. No. | Name of the Active substance(s)     | Activity(ies)           |
|--------|-------------------------------------|-------------------------|
| 1.     | Argatroban USP                      | Manufacturing & Packing |
| 2.     | Bexarotene IH                       | Manufacturing & Packing |
| 3.     | Cidofovir USP                       | Manufacturing & Packing |
| 4.     | Clofarabine IH                      | Manufacturing & Packing |
| 5.     | Fingolimod Hydrochloride IH         | Manufacturing & Packing |
| 6.     | Foscarnet Sodium USP                | Manufacturing & Packing |
| 7.     | Ibandronate Sodium Monohydrate IH   | Manufacturing & Packing |
| 8.     | Midodrine Hydrochloride USP         | Manufacturing & Packing |
| 9.     | Olsalazine Sodium Ph. Eur.          | Manufacturing & Packing |
| 10.    | Prochlorperazine Edisylate USP      | Manufacturing & Packing |
| 11.    | Trimethobenzamide Hydrochloride USP | Manufacturing & Packing |
| 12.    | Treosulfan IH                       | Manufacturing & Packing |
| 13.    | Trientine Hydrochloride USP         | Manufacturing & Packing |
| 14.    | Tenofovir Alafamide Fumarate IH     | Manufacturing & Packing |

**ITEM(S) Fourteen (14) Only**

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substances for the purpose of export only, as the above mentioned active substances are not approved for manufacture or sale in India.

The Written Confirmation remains valid until: **02<sup>nd</sup> July, 2022**

Signature

Stamp of the authority and date



**07 OCT 2019**

Handwritten notes and signatures:   
A large handwritten signature   
A date '4-10-14'   
A small signature '1/2 #'